問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of General Internal Medicine

Digestive System Department

更新時間:2023-09-19

鄭雅婷
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

25Cases

2023-06-01 - 2026-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-11-09 - 2032-11-22

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-01-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2026-03-08 - 2027-06-15

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2026-01-01 - 2032-03-10

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2021-03-01 - 2026-12-30

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-01-12 - 2026-09-11

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Condition/Disease

    Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  • Test Drug

    Efruxifermin

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting2Sites

Study ended1Sites

2017-03-17 - 2023-03-17

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)
  • Condition/Disease

    Nonalcoholic Steatohepatitis

  • Test Drug

    Selonsertib

Participate Sites
5Sites

Terminated4Sites

2017-03-03 - 2023-02-28

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
  • Condition/Disease

    Nonalcoholic Steatohepatitis(NASH)

  • Test Drug

    Selonsertib

Participate Sites
20Sites

Terminated18Sites

2019-10-04 - 2020-12-28

Phase I

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GS-4224 in Healthy Volunteers and Subjects with the Chronic Hepatitis B (CHB) Virus
  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-4224 Film-coated Tablets, 10mg and 100mg

Participate Sites
4Sites

Recruiting4Sites

1 2 3